| Vaccine description | |
|---|---|
| Target | SARS-CoV-2 |
| Vaccine type | Inactivated |
| Clinical data | |
| Routes of administration | Intramuscular |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
CoviVac (Russian:КовиВак) is aninactivated virus-basedCOVID-19 vaccine developed by theChumakov Centre [ru],[2] which is an institute of theRussian Academy of Sciences.[3] It was approved for use inRussia in February 2021, being the third COVID-19 vaccine to get approval in Russia.[2] It obtained a permission forphase III clinical trial on 2 June 2021.[4]
The CoviVac shot is given in two doses, 14 days apart. It is transported and stored at normal refrigerated temperatures, of 2 to 8 degreesCelsius (35.6 to 46.4Fahrenheit).[2]
Efficacy has not yet been established in a phase III clinical trial.[citation needed]
One dose of 0.5ml is composed only of 3μg or more of SARS-CoV-2strain AYDAR-1antigen inactivated bybeta-propiolactone and the followingexcipients:[5]
As aninactivated vaccine, CoviVac uses a more traditional technology that is similar to the inactivatedpolio vaccine. Initially, a sample ofSARS-CoV-2 strain AYDAR-1 was isolated by the Chumakov Center at theRussian Academy of Sciences and used to grow large quantities of the virus usingvero cells. From then on, the viruses are soaked in beta-propiolactone, which deactivates them by binding to their genes, while leaving other viral particles intact. The resulting inactivated viruses are then mixed with an aluminium-basedadjuvant.[6]
On 21 September 2020, phase I/II trials started and was expected to last through 15 October 2020.[7][8]
In early 2021, phase III trials started and is expected to end on 30 December 2022.[9]
On 20 February 2021, PresidentVladimir Putin announced that the vaccine was approved.[2]
.png) | This article about COVID-19 vaccines is astub. You can help Wikipedia byexpanding it. |
 | This article aboutvaccines orvaccination is astub. You can help Wikipedia byexpanding it. |
.svg)